Adverse events associated with smallpox vaccination in the United States, January-October 2003. - Test2 - elhamkhani - TriplyDB

Adverse events associated with smallpox vaccination in the United States, January-October 2003.

Adverse events associated with smallpox vaccination in the United States, January-October 2003.

http://www.wikidata.org/entity/Q30231595

about

Smallpox vaccines for biodefense: need and feasibility What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review Estimating the Size of the U.S. Population at Risk of Severe Adverse Events from Replicating Smallpox Vaccine.Finding and removing highly connected individuals using suboptimal vaccines.Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteers Comparison of smallpox outbreak control strategies using a spatial metapopulation model.Smallpox transmission and control: spatial dynamics in Great Britain.Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy A quantitative rabbit model of vaccinia keratitis.Evaluation of therapeutic interventions for vaccinia virus keratitis Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications.Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.Adversomics: a new paradigm for vaccine safety and design.Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Antibody responses to vaccinia membrane proteins after smallpox vaccination.Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics The strategic use of novel smallpox vaccines in the post-eradication world.Unintentional transfer of vaccinia virus associated with smallpox vaccines: ACAM2000(®) compared with Dryvax(®).Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.Vaccinia virus A35R inhibits MHC class II antigen presentation.Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.Genomic identification of human vaccinia virus keratoconjunctivitis and its importance as a laboratory-acquired infection.Vaccination-Related Side Effects, Humoral Immunity, and Adverse Events during the Civilian Smallpox Vaccination Campaign, Arkansas, 2003.Poxvirus countermeasures during an emergency in the United States.Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox.

P2860

Q22305942-C1D446C0-1C0E-495F-AD45-7400E83D6A6C Q26738973-61EB5546-4D01-4B53-9622-809BA1042C2C Q28485174-D847B345-4F0F-47DE-A56E-9542B320D91D Q30151714-B5AD1F46-F9AF-488C-B64F-920979F0B766 Q30224717-F06D3BBA-3BC4-4C80-8738-603F83181E2B Q30228332-C7EE8F32-03F2-4668-8208-CF58175E505D Q30230157-4BDEFDB6-0630-49BB-95E4-E80C8EF07253 Q30477988-51E0356E-E7BA-44B0-9EA6-7A6D42F1B92A Q30977303-1EB87BDC-E2A3-4B9F-972E-A0DD999BA206 Q33729509-5153BCC6-BAF0-4767-81AE-1FA1C95A7727 Q33754697-758672CF-8A9F-45E7-811B-1883112BDF39 Q34135490-E47EE7ED-98E5-4E48-9D62-39E3B89E255A Q34772694-2B56E4D7-A2FD-4FEF-BF27-30A84E4623AA Q34810232-24533811-1B2B-4089-ABE3-F5A63699D2AC Q35166824-7F3DE8E4-5F1D-4CD7-A551-2BF67234806D Q35557123-A134301E-51F1-4BAD-A111-C42933B481AD Q35571248-D750DC84-7858-4110-85E9-090A9C4C0FB4 Q35826728-AA6D1BA8-9D83-4AB4-839F-70FF638102B6 Q35830974-2B5568E3-C496-44AC-AD47-775366B9DD4F Q36057928-2D7C41D5-E97B-4B77-ADC2-3EC198814392 Q36242667-6ACB7CB7-DC4B-4F43-91F0-93014A704858 Q36477717-22DE5139-A8C1-46BC-B5D6-09A4A8C3A62B Q36488876-1D459D1A-CF05-4002-8C33-39D8A366D901 Q36599215-665211AF-C322-48EC-8067-F21E93837E89 Q36747784-673DD166-EEDB-49A0-88D5-86BE7D109AFC Q36845650-392CCD74-5731-483B-B734-D5DA0FDCF2A3 Q36869365-4C63F2BD-07AC-4C92-96BD-485E29B25893 Q37033408-A73A1586-CE39-4A67-8700-316DEA25B060 Q37191938-621B0C3D-36D6-4607-9C1A-E1F0039FA744 Q37909421-AEDE9DF7-F325-44B0-BC5F-AC55A66D0F9C Q38097615-6C3AA224-B4D9-4192-8DD5-94D102171F49 Q38222113-2D0B8362-1E62-4D1B-ABE8-5FC42F1E968C Q39390434-BF1FA79D-EA2A-40D2-94BB-761A2E8CF870 Q39753158-23E246DC-29FA-4043-9F74-771B3946C278 Q40083001-BA4172F3-4A71-4110-9E95-4CAA718FDEB1 Q40348698-FDF8B174-E09B-4853-8A11-AC963D184FFA Q40869018-118DA955-B372-4783-9FD3-24053B51B625 Q41681967-A38A6E36-97C0-4501-87E3-6EBE37F90397 Q42143723-8065634A-98F1-45E6-983C-E1121783A890 Q42619783-EE3C8519-7682-496A-B0FC-0953338B8393

P2860

Adverse events associated with smallpox vaccination in the United States, January-October 2003.

http://www.wikidata.org/entity/Q30231595

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Adverse events associated with ...... States, January-October 2003.

@ast

Adverse events associated with ...... States, January-October 2003.

@en

type

label

Adverse events associated with ...... States, January-October 2003.

@ast

Adverse events associated with ...... States, January-October 2003.

@en

prefLabel

Adverse events associated with ...... States, January-October 2003.

@ast

Adverse events associated with ...... States, January-October 2003.

@en

P1433

Q30231595-22A5D421-485B-409F-A66B-463D27BC314D

P1476

Q30231595-AE2CF103-3C3E-4A0A-A75D-E43CA8CF9A77

P2093

Q30231595-1E99F132-B1D5-4BFB-9894-60D28D93ABC4

Q30231595-1F26A368-340F-4455-831E-F56DD5D8CC17

Q30231595-1F37B38D-C87F-4C8E-A7E4-3E155C7D1FE9

Q30231595-27E2A122-3BD6-443D-8308-14852349E111

Q30231595-3C342C6A-32E2-42E7-88E5-F6D33CBDA3DB

Q30231595-418FA7BD-0BBB-4D3D-A464-7B9A036E028D

Q30231595-43C86F8F-899C-4889-8E6F-9EC009A36034

Q30231595-6239068F-C323-4109-96FF-E025C8AD638B

Q30231595-6751F865-03E5-4797-BF13-4ECE143198A7

Q30231595-7ED30326-99F4-41A5-B302-851DE3708DE3

P304

Q30231595-81CB2BC0-2188-4D53-A348-0A5CB1F3DC9A

P31

Q30231595-DF20AECE-F101-4EDE-AB58-3484C29E3465

P356

Q30231595-F942F9E8-EB81-4605-BFB3-D58D3D66E08F

P407

Q30231595-4B89A19D-EE8B-4C47-A4E2-C58D0087DBBE

P433

Q30231595-2195FA58-26FB-4382-8D68-2466BE337CEE

P478

Q30231595-FD2F84B2-9695-45BF-AD78-785A63161123

P50

Q30231595-B4735724-FB79-4CD8-BD12-21824272A28B

P577

Q30231595-2012F450-37F8-4DDA-9C8B-F0FD1C4A078D

P5875

Q30231595-A7980448-4B4A-4326-AA8D-7FBEC6611194

P698

Q30231595-435FD0DD-1BF7-4CB6-88B8-6AD479AD9B7D

P921

Q30231595-9F55CB6D-ED79-4677-A671-A4154B872D3F

P356

JAMA.294.21.2734

P1433

Journal of the American Medical Association

P1476

Adverse events associated with ...... States, January-October 2003.

@en

P2093

Charles Vitek

http://www.w3.org/2001/XMLSchema#string

Christine G Casey

http://www.w3.org/2001/XMLSchema#string

Claudia Vellozzi

http://www.w3.org/2001/XMLSchema#string

Eric E Mast

http://www.w3.org/2001/XMLSchema#string

Gina Mootrey

http://www.w3.org/2001/XMLSchema#string

Inger Damon

http://www.w3.org/2001/XMLSchema#string

James D Heffelfinger

http://www.w3.org/2001/XMLSchema#string

John K Iskander

http://www.w3.org/2001/XMLSchema#string

Juliette Morgan

http://www.w3.org/2001/XMLSchema#string

La Mar Hasbrouck

http://www.w3.org/2001/XMLSchema#string

P304

2734-2743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.294.21.2734

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

294

http://www.w3.org/2001/XMLSchema#string

P50

David L Swerdlow

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7436638

http://www.w3.org/2001/XMLSchema#string

P698

16333009

http://www.w3.org/2001/XMLSchema#string

P921